Cairo 2003a.

Methods	Randomised, parallel group, multicentre trial (Europe). ITT: unclear. Withdrawals: unclear.
Participants	Baseline characteristics: 241 participants screened (BL and BLL: 51.3%), 195 randomised (standard dose: 96; reduced intensity: 99). Median age: 8 years (range: 1 to 19). Tumour staging: REAL. Diagnosis: not reported. Entry criteria: ≤ 21 years; advanced disease (bone marrow and/or CNS, B‐cell NHL (large‐cell lymphoma, BL and BLL)). Exclusion criteria: not described.
Interventions	A standard‐treatment course consisting of a consolidation phase and 4 courses of maintenance regimens compared with a reduced‐intensity regimen similar to standard dose except that the consolidation drugs are given at two‐thirds of the standard doses and no maintenance phase was given (see.Table 1). Tretament duration: not reported. Follow‐up: median 3.25 years.
Outcomes	Overall survival. Event‐free survival.
Notes	Unpublished conference abstract. Study type: remission induction.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described; perhaps due to constraints of the size of the abstract.